Ibrance

Palbociclib, the active ingredient in Ibrance, is a CDK4/6 inhibitor presented as a tablet for oral use. It selectively blocks cyclin‑dependent kinases 4 and 6, halting cell‑cycle progression in cancer cells. The drug is indicated for hormone receptor‑positive, HER2‑negative advanced or metastatic breast cancer in adult patients, improving progression‑free survival when combined with endocrine therapy.

GNH USA supplies Ibrance as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Ibrance is used in the treatment of hormone receptor‑positive, HER2‑negative breast cancer, targeting cell‑cycle pathways. - Advanced breast cancer: improves progression‑free survival when combined with endocrine therapy. - Metastatic breast cancer: delays disease progression in patients with HR‑positive, HER2‑negative tumors. - Postmenopausal women with HR‑positive, HER2‑negative disease: enhances response to letrozole or fulvestrant.

Palbociclib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count. - Leukopenia: decreased white blood cells. - Anemia: fatigue due to low red cells. - Nausea: upset stomach. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils. - Pulmonary embolism: blood clot in lungs. - Severe liver enzyme elevation: increased ALT/AST.

When prescribing Palbociclib, several safety considerations should be observed. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check ALT/AST before and during therapy. - Avoid use in pregnancy: drug is contraindicated; ensure effective contraception. - Adjust dose in renal impairment: consider dose reduction for moderate renal dysfunction. - Review concomitant myelosuppressive agents: avoid combining with other drugs that lower blood cells. - Store at ambient temperature: keep tablets in original container, protect from moisture.

Palbociclib interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase palbociclib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce drug levels. - Concurrent myelosuppressive chemotherapy: heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem): may modestly increase exposure. - Moderate CYP3A4 inducers (e.g., phenytoin, St. John’s wort): may modestly decrease exposure. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.